Biomarkers of Aging Conference 2025 convenes leading researchers, clinicians and industry in Boston to advance consensus on measuring aging.
The Biomarkers of Aging Conference 2025 takes place between the 20th and 21st of October at Harvard Medical School in Boston. Hosted by the Biomarkers of Aging Consortium, the two-day meeting will bring together world-leading academics, clinicians and industry experts to advance the development and validation of aging biomarkers – the tools that will allow longevity science to move closer to the clinic and to translational application.
Now in its third year, the Conference has expanded from a one-day kickoff event into a major international fixture; the 2025 edition builds on that growth, reflecting both the momentum in biomarker science and the urgency of establishing standards that can be applied in trials, in practice and eventually in regulatory pathways.
This year’s program will feature a keynote from Professor Andrea Maier, president of the Healthy Longevity Medicine Society, as well as sessions on immune aging developed in collaboration with XPRIZE. Attendees can also expect updates from the Consortium’s challenge series, a dedicated focus on biomarkers of brain aging, and more than 100 posters and flash talks showcasing early-career investigators – an agenda that reflects both scientific depth and the field’s growing diversity.
Longevity.Technology: The Biomarkers of Aging Conference is more than just another entry in the crowded scientific calendar; it represents a serious attempt to draw together disparate efforts in academia, biotech and clinical practice and to forge consensus on what constitutes a valid measure of biological age. The validation of biomarkers is no mere academic exercise – it is central to regulatory approval, investment confidence and the clinical adoption of therapies. And this year’s emphasis on clinical integration is significant: biomarkers will not remain research curiosities for long, they must be explained to patients, deployed by doctors and trusted in practice. Bringing open science, global collaboration and the healthy longevity community under one roof in Boston reflects both ambition and necessity, and to find out more, we sat down with Executive Committee members Drs Jesse Poganik and Andrea Cipriano.
Jesse Poganik on…
Bringing biomarkers into the clinic
We’re trying to move closer and closer to the clinic with biomarkers of aging. Part of that is working with other groups that have the same goal, and part of it is bringing in the clinicians who will be the users of biomarkers of aging in the clinic. I think that will be one of the most exciting things for me about this year’s conference – the increased emphasis on clinical integration of biomarkers of aging.
Why clinician perspectives matter
Clinicians are going to be the ones who are using these biomarkers in the clinic, so of course we need to have them on our side. But it’s also important to get their perspective, because they think in a very different way than researchers – their priorities are different and the way they need to explain biomarkers to patients is very different from how we explain them to a research audience. It’s really essential to have that perspective in addition to having them as the end users.
Andrea Cipriano on…
Why consensus matters
One of the missions of the consortium is actually reaching consensus, and I think it’s the motivation that brought us to develop it in the first place. Developing a biomarker and reaching consensus on something that is still difficult to define is extremely challenging. Every organ has a different aging base, so the goal is to decipher the different dimensions of aging, and that might lead to developing different types of biomarkers based on the biological process we want to study.
The case for longitudinal studies
If you don’t give AI good food – good data – it’s going to be difficult. What we need in the field is longitudinal studies, meaning that we need to follow people every year and combine functional measures with molecular data. Last year we ran a pilot as a training exercise to understand how much it takes in terms of IRB approval and recruitment, and we collected functional information like walking tests and balance tests. At this conference we will show how such longitudinal studies can be run and why they are essential if we want to measure aging in healthy populations rather than confounded by chronic disease.
The Biomarkers of Aging Conference runs 20th & 21st October The Joseph B Martin Conference Center, Harvard Medical School, Boston, Massachusetts. Find out more – CLICK HERE.
#Biomarkers #aging #moving #closer #closer #clinic